Literature DB >> 21859963

Proteinase-activated receptors 1 and 2 exert opposite effects on renal renin release.

Klaus Höcherl1, Melanie Gerl, Frank Schweda.   

Abstract

Proteinase-activated receptors (PARs) 1 to 4 are highly expressed in the kidney and are involved in the regulation of renal hemodynamics and tubular function. Since intravascular infusion of the proteinase thrombin, which activates PARs, has been shown to decrease plasma renin activity in rats, we investigated the effects of the respective PAR subtypes on renin release using the isolated perfused mouse kidney model. Thrombin dose-dependently reduced perfusate flow and inhibited renin secretion rates (RSRs) that had been prestimulated by the β-adrenoreceptor agonist isoproterenol. The suppression of RSRs was prevented by the selective PAR1 inhibitor SCH79797, and direct activation of PAR1 by TFLLR mimicked the effects of thrombin on RSRs and vascular tone. Moreover, TFLLR suppressed the stimulations of RSRs in response to the loop diuretic bumetanide, to prostaglandin E(2), or to a decrease in renal perfusion pressure but not in response to a reduction in extracellular calcium. The PAR2-activating peptide SLIGRL concentration dependently increased RSR and perfusate flow. The stimulation of RSRs by SLIGRL was markedly attenuated by N(G)-nitro-L-arginine methyl ester, suggesting an NO-dependent mechanism. Activation of PAR4 by AYPGKF did not modulate RSRs or perfusate flow. PAR1 and PAR2 immunoreactivity were detected in the juxtaglomerular region and were colocalized with renin immunoreactivity. Our data provide evidence that PAR1 activation inhibits renal renin secretion and induces renal vasoconstriction, whereas PAR2 activation stimulates renin release and induces vasodilation mainly via the release of NO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859963     DOI: 10.1161/HYPERTENSIONAHA.111.173229

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 2.  Protease-activated receptors in kidney disease progression.

Authors:  Oleg Palygin; Daria V Ilatovskaya; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-12

Review 3.  Physiology and pathophysiology of the plasminogen system in the kidney.

Authors:  Per Svenningsen; Gitte Rye Hinrichs; Rikke Zachar; Rikke Ydegaard; Boye L Jensen
Journal:  Pflugers Arch       Date:  2017-06-27       Impact factor: 3.657

4.  Role of protease-activated receptor 2 in regulation of renin synthesis and secretion in mice.

Authors:  Lena R Thurner; Klaus Höcherl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-06-27       Impact factor: 3.000

Review 5.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.